Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Hold" at StockNews.com

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Other research analysts also recently issued research reports about the company. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. JMP Securities dropped their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.60.

Ironwood Pharmaceuticals Price Performance

IRWD stock traded down $0.03 during trading on Friday, reaching $1.49. 3,162,026 shares of the company were exchanged, compared to its average volume of 2,587,505. Ironwood Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $9.59. The company has a market capitalization of $238.44 million, a price-to-earnings ratio of -49.67 and a beta of 0.37. The company has a 50-day moving average of $3.10 and a two-hundred day moving average of $3.81.

Remove Ads

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. On average, analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Insider Activity at Ironwood Pharmaceuticals

In other news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares of the company's stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 192,381 shares of company stock worth $338,591 over the last ninety days. Insiders own 12.90% of the company's stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $1,888,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Ironwood Pharmaceuticals by 6.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 286,990 shares of the biotechnology company's stock valued at $1,271,000 after acquiring an additional 17,265 shares during the period. State of Wyoming boosted its stake in Ironwood Pharmaceuticals by 37.8% during the fourth quarter. State of Wyoming now owns 41,858 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 11,479 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $36,000. Finally, ProShare Advisors LLC increased its stake in Ironwood Pharmaceuticals by 28.9% in the fourth quarter. ProShare Advisors LLC now owns 50,204 shares of the biotechnology company's stock valued at $222,000 after purchasing an additional 11,267 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.